J&J's Q3 pharma sales increase by 5% as it awaits Remicade decision
This article was originally published in Scrip
Executive Summary
Johnson & Johnson reported third-quarter sales of $15.0 billion, a drop of 1% of the same period last year. However, the company raised its earnings guidance for the full year to $4.70-$4.80 per share, reflecting recent currency exchange rates and excluding special items.